Alterity Therapeutics (ATHE)
4.70
-0.28 (5.62%)
Latest Headlines
Jones Trading Starts Alterity Therapeutics (ATHE) at Buy
June 29, 2026 4:31 PM - StreetInsider
Form 4 ALTERITY THERAPEUTICS For: Jun 15 Filed by: Babarczy Julian Michael
June 23, 2026 7:58 PM - SEC Filing
Form 4 ALTERITY THERAPEUTICS For: Jun 15 Filed by: Gozlan Lawrence Bernard
June 23, 2026 7:38 PM - SEC Filing
Ladenburg Thalmann Assumes Alterity Therapeutics (ATHE) at Buy
June 16, 2026 8:04 AM - StreetInsider
Form 6-K ALTERITY THERAPEUTICS For: Jun 30
June 3, 2026 6:05 AM - SEC Filing
Form 6-K ALTERITY THERAPEUTICS For: May 31
May 29, 2026 6:08 AM - SEC Filing
Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA
May 19, 2026 7:25 AM - StreetInsider
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
May 19, 2026 7:25 AM - Globe NewsWire
Form 6-K ALTERITY THERAPEUTICS For: May 31
May 19, 2026 6:06 AM - SEC Filing
Form 424B3 Alterity Therapeutics
May 12, 2026 3:40 PM - SEC Filing
Form 6-K ALTERITY THERAPEUTICS For: May 31
May 12, 2026 6:07 AM - SEC Filing
Alterity publishes study on MRI biomarker for multiple system atrophy
May 11, 2026 7:25 AM - StreetInsider
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
May 11, 2026 7:25 AM - Globe NewsWire
Form 6-K ALTERITY THERAPEUTICS For: May 31
May 11, 2026 6:04 AM - SEC Filing
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
May 7, 2026 7:25 AM - Globe NewsWire
Form 6-K ALTERITY THERAPEUTICS For: May 31
May 7, 2026 6:08 AM - SEC Filing
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
April 30, 2026 7:25 AM - Globe NewsWire
Form 6-K ALTERITY THERAPEUTICS For: Apr 30
April 30, 2026 6:18 AM - SEC Filing
Form 6-K ALTERITY THERAPEUTICS For: Apr 30
April 30, 2026 6:16 AM - SEC Filing
Form 3 ALTERITY THERAPEUTICS For: Apr 17 Filed by: Cunningham Ann Michelle
April 29, 2026 8:05 PM - SEC Filing
Form 6-K ALTERITY THERAPEUTICS For: Apr 30
April 29, 2026 8:10 AM - SEC Filing
Alterity Therapeutics receives FDA alignment on ATH434 manufacturing plans
April 27, 2026 7:25 AM - StreetInsider
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
April 27, 2026 7:25 AM - Globe NewsWire
Form 6-K ALTERITY THERAPEUTICS For: Apr 30
April 27, 2026 6:22 AM - SEC Filing
Form 6-K ALTERITY THERAPEUTICS For: Apr 30
April 27, 2026 6:22 AM - SEC Filing
Full Article List
